Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Exploratory Study of the Safety and Preliminary Efficacy of Danicamtiv in Stable Ambulatory Participants With Primary Dilated Cardiomyopathy Due to Either MYH7 or TTN Variants or Other Causalities

Next Previous
Search
Trial Profile

An Open-Label, Exploratory Study of the Safety and Preliminary Efficacy of Danicamtiv in Stable Ambulatory Participants With Primary Dilated Cardiomyopathy Due to Either MYH7 or TTN Variants or Other Causalities

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 29 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Danicamtiv (Primary)
  • Indications Dilated cardiomyopathy
  • Focus Adverse reactions; Proof of concept
  • Sponsors Bristol-Myers Squibb; MyoKardia

Most Recent Events

  • 26 Mar 2024 Status changed from recruiting to discontinued.
  • 20 Dec 2023 Planned End Date changed from 3 Jan 2025 to 19 Feb 2026.
  • 20 Dec 2023 Planned primary completion date changed from 8 Dec 2023 to 29 Feb 2024.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top